CheckMate 153 trial: how long should nivolumab be taken for?
Phase 1 study of anti-PD-L1 durvalumab plus gefitinib in TKI-naïve patients with EGFR-mutant NSCLC
Immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
Genetic evolution of NSCLC
TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer